X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24027) 24027
Book Review (1872) 1872
Newsletter (1694) 1694
Publication (941) 941
Conference Proceeding (108) 108
Book Chapter (50) 50
Dissertation (29) 29
Newspaper Article (15) 15
Transcript (6) 6
Magazine Article (5) 5
Paper (5) 5
Government Document (4) 4
Web Resource (4) 4
Report (3) 3
Journal / eJournal (2) 2
Book / eBook (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (19826) 19826
humans (18682) 18682
etoposide (11946) 11946
male (10168) 10168
oncology (9819) 9819
female (9783) 9783
etoposide - administration & dosage (9160) 9160
antineoplastic combined chemotherapy protocols - therapeutic use (9015) 9015
adult (7477) 7477
middle aged (7430) 7430
chemotherapy (6606) 6606
aged (5310) 5310
cancer (5238) 5238
cisplatin - administration & dosage (4045) 4045
etoposide - pharmacology (3933) 3933
treatment outcome (3527) 3527
cisplatin (3374) 3374
antineoplastic combined chemotherapy protocols - adverse effects (3158) 3158
adolescent (3085) 3085
combined modality therapy (3049) 3049
hematology (2947) 2947
lung neoplasms - drug therapy (2896) 2896
cyclophosphamide - administration & dosage (2813) 2813
animals (2761) 2761
apoptosis (2675) 2675
etoposide - therapeutic use (2651) 2651
antineoplastic combined chemotherapy protocols - administration & dosage (2412) 2412
etoposide - adverse effects (2376) 2376
doxorubicin - administration & dosage (2306) 2306
prognosis (2236) 2236
vincristine - administration & dosage (2152) 2152
research (2127) 2127
care and treatment (2081) 2081
child (1892) 1892
survival rate (1868) 1868
drug administration schedule (1824) 1824
therapy (1811) 1811
remission induction (1772) 1772
carboplatin - administration & dosage (1730) 1730
apoptosis - drug effects (1668) 1668
neoplasm staging (1660) 1660
retrospective studies (1627) 1627
mice (1623) 1623
cyclophosphamide (1622) 1622
survival analysis (1601) 1601
disease-free survival (1581) 1581
pharmacology & pharmacy (1563) 1563
carcinoma, small cell - drug therapy (1517) 1517
child, preschool (1459) 1459
tumors (1443) 1443
carboplatin (1441) 1441
dose-response relationship, drug (1435) 1435
antineoplastic agents - pharmacology (1419) 1419
abridged index medicus (1408) 1408
biochemistry & molecular biology (1405) 1405
bleomycin - administration & dosage (1403) 1403
cytarabine - administration & dosage (1388) 1388
carcinoma (1360) 1360
cell line, tumor (1351) 1351
ifosfamide - administration & dosage (1345) 1345
follow-up studies (1318) 1318
transplantation (1275) 1275
survival (1272) 1272
lung neoplasms - pathology (1199) 1199
tumor cells, cultured (1191) 1191
time factors (1189) 1189
radiotherapy (1186) 1186
doxorubicin (1154) 1154
cell biology (1144) 1144
dna damage (1134) 1134
drugs (1133) 1133
expression (1096) 1096
antineoplastic agents - therapeutic use (1090) 1090
infant (1090) 1090
aged, 80 and over (1088) 1088
trial (1085) 1085
methotrexate - administration & dosage (1038) 1038
analysis (1034) 1034
antineoplastic agents, phytogenic - pharmacology (1013) 1013
children (983) 983
combination chemotherapy (958) 958
salvage therapy (957) 957
lung cancer (947) 947
pediatrics (940) 940
medicine & public health (925) 925
transplantation, autologous (924) 924
phase-ii (918) 918
recurrence (914) 914
prednisone - administration & dosage (901) 901
cisplatin - adverse effects (893) 893
ifosfamide (886) 886
leukemia (884) 884
carcinoma, non-small-cell lung - drug therapy (882) 882
young adult (871) 871
testicular neoplasms - drug therapy (850) 850
drug resistance, neoplasm (845) 845
hematopoietic stem cell transplantation (840) 840
prospective studies (836) 836
drug resistance (819) 819
surgery (815) 815
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (23619) 23619
Japanese (1039) 1039
German (285) 285
French (273) 273
Chinese (241) 241
Spanish (99) 99
Russian (93) 93
Polish (54) 54
Italian (45) 45
Korean (35) 35
Hungarian (20) 20
Portuguese (17) 17
Czech (12) 12
Turkish (11) 11
Dutch (8) 8
Serbian (8) 8
Hebrew (6) 6
Croatian (5) 5
Danish (2) 2
Norwegian (2) 2
Romanian (2) 2
Swedish (2) 2
Ukrainian (2) 2
Arabic (1) 1
Bulgarian (1) 1
Indonesian (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


La Revue de medecine interne, ISSN 0248-8663, 06/2017, Volume 38, p. A205-A206
Le syndrome d'activation macrophagique (SAM) ou lympho-histiocytose hemophagocytaire est une entite clinico-biologique rare pouvant compliquer plusieurs... 
Etoposide
Journal Article
La Revue de medecine interne, ISSN 0248-8663, 06/2017, Volume 38, p. A205
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/j.revmed.2017.03.303 Le... 
Etoposide
Journal Article
EXCLI Journal, 01/2015, Volume 14, pp. 95 - 108
Journal Article
Journal of Thermal Analysis and Calorimetry, ISSN 1388-6150, 03/2014, Volume 115, Issue 3, p. 2369
The effects of podophyllotoxin (PPT), etoposide (VP16), and teniposide (VM26) on the growth of Tetrahy mena thermophila [BF.sub.5] (T.t.[BF.sub.5]) was... 
Etoposide
Journal Article
Science, ISSN 0036-8075, 7/2011, Volume 333, Issue 6041, pp. 459 - 462
Type II topoisomerases (TOP2s) resolve the topological problems of DNA by transiently cleaving both strands of a DNA duplex to form a cleavage complex through... 
Protein isoforms | Molecules | Molecular structure | DNA | Drug interactions | REPORTS | Antineoplastics | Biochemistry | Nucleotides | Genetic mutation | Monomers | TARGET | DNA TOPOISOMERASE | COMPLEX | ENZYME | CRYSTAL-STRUCTURE | MULTIDISCIPLINARY SCIENCES | RESISTANCE | ALPHA | CLEAVAGE | CANCER | BETA | Humans | Protein Multimerization | Crystallography, X-Ray | Drug Resistance, Neoplasm | Structure-Activity Relationship | DNA-Binding Proteins - metabolism | Topoisomerase II Inhibitors - chemistry | DNA Topoisomerases, Type II - chemistry | Protein Structure, Quaternary | Protein Structure, Tertiary | DNA Topoisomerases, Type II - metabolism | Catalytic Domain | Etoposide - analogs & derivatives | Etoposide - pharmacology | Models, Molecular | Etoposide - metabolism | Mutant Proteins - metabolism | Topoisomerase II Inhibitors - pharmacology | DNA - metabolism | Topoisomerase II Inhibitors - metabolism | DNA-Binding Proteins - genetics | DNA-Binding Proteins - chemistry | DNA - chemistry | Base Pairing | Mutant Proteins - chemistry | DNA Topoisomerases, Type II - genetics | Etoposide - chemistry | Mutation | Antimitotic agents | Topoisomerases | Etoposide | Physiological aspects | Research | Antineoplastic agents | Health aspects | Proteins | Enzymes | Pharmacology | Deoxyribonucleic acid--DNA | Cancer | Index Medicus
Journal Article
Apoptosis - An International Journal on Programmed Cell Death, ISSN 1360-8185, 06/2008, Volume 13, Issue 6, p. 756
Tumour necrosis factor related apoptosis inducing ligand (TRAIL) binds to death receptor 4 (DR4) activating the apoptotic signalling pathway. DNA damaging... 
Etoposide
Journal Article
British Journal of Haematology, ISSN 0007-1048, 04/2015, Volume 169, Issue 2, pp. 188 - 198
This prospective multi‐institutional phase II study was designed to assess the efficacy and safety of dose‐adjusted EPOCH (etoposide, prednisone, vincristine,... 
vincristine | and rituximab | large B‐cell lymphoma | cyclophosphamide | doxorubicin | dose‐adjusted‐EPOCH‐R (etoposide, prednisone | high‐risk patients | cell of origin | Dose-adjusted-EPOCH-R (etoposide, prednisone | Cyclophosphamide | And rituximab | Cell of origin | Large B-cell lymphoma | High-risk patients | Doxorubicin | Vincristine | SURVIVAL | DLBCL | BCL-2 GENE | REGIMEN | GERMINAL CENTER | CHEMOTHERAPY | high-risk patients | large B-cell lymphoma | PROTEIN EXPRESSION | dose-adjusted-EPOCH-R (etoposide | NON-HODGKINS-LYMPHOMA | CHOP | TISSUE MICROARRAY | prednisone | HEMATOLOGY | Doxorubicin - therapeutic use | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Neoplasm Grading | Adult | Female | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Lymphoma, Large B-Cell, Diffuse - pathology | Rituximab | Etoposide - therapeutic use | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Medical research | Anthracyclines | Corticosteroids | Analysis | Clinical trials | Medicine, Experimental | Etoposide | Lymphomas | Prednisone | Index Medicus
Journal Article
Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/ gastroesophageal junction, 12/2006
Background: Unresectable and metastatic gastric cancers carry a poor and dismal prognosis. Several phase II studies have identified effective anticancer drugs.... 
Cisplatin, etoposide, gastric, gastroesophageal, paclitaxel
Journal
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 04/2010, Volume 53, Issue 7, pp. 2814 - 2824
Journal Article
Journal Article
Molecular and Cellular Biochemistry, ISSN 0300-8177, 07/2019, Volume 457, Issue 1-2, p. 21
Journal Article
Materials Science & Engineering C, ISSN 0928-4931, 09/2019, Volume 102, p. 96
In this article, we have reported the inclusion complex behaviors and their pharmaceutical application of anticancer drug property of Etoposide with... 
Analysis | Etoposide | Cyclodextrins
Journal Article
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 10/2011, Volume 103, Issue 19, pp. 1452 - 1460
Background The combination of chemotherapy with thoracic radiotherapy (TRT) compared with TRT alone has been shown to confer a survival advantage for good... 
IRRADIATION | CARBOPLATIN | CISPLATIN | VINORELBINE | ONCOLOGY | THERAPY-ONCOLOGY-GROUP | CHEMORADIOTHERAPY | RADIOTHERAPY | CHEMOTHERAPY | RADIATION-THERAPY | PACLITAXEL | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Multivariate Analysis | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - radiotherapy | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Time Factors | Vinblastine - adverse effects | Aged, 80 and over | Adult | Dose Fractionation | Chemotherapy, Adjuvant | Odds Ratio | Radiotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung - pathology | Radiotherapy Dosage | Etoposide - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Treatment Outcome | Disease Progression | Canada | Confounding Factors (Epidemiology) | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Etoposide | Research | Lung cancer, Non-small cell | Drug therapy | Radiotherapy | Health aspects | Survival analysis | Oncology | Chemotherapy | Lung cancer | Clinical outcomes | Index Medicus
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.